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•	 Long-Term Results After 
Treatment for Recurrent 
Thymoma: A Multicenter 
Analysis
14 with other paraneoplastic conditions, in which 
75.3% had surgery and 17.3% had radiotherapy and/
or chemotherapy. The study found no significant 
difference in disease-free survival between the groups 
with and without adjuvant therapy (chemotherapy, 
64.0 ± 41.3 months versus 91.5 ± 76.4 months, 
respectively; radiotherapy, 93.0 ± 62.3 months versus 
86.2 ± 72.8 months, respectively). There were 59 cases 
of local recurrences and 15 hematogenous distant 
recurrences. Twenty-five of 61 cases had been assigned 
with more aggressive WHO class at recurrence relative 
to that at initial thymectomy, without changing the 
prognosis of patients. The 5-year and 10-year survival 
rates were 94.8% and 71.7%, respectively, after initial 
thymectomy, and 82.4% and 65.4%, respectively, after 
treatment for recurrence (when a R0-re-resection was 
included). The results also showed an association of 
a higher risk of re-relapse with the recurrence site 
(hematogenous diffusion, p = 0.01). To conclude, 
thymoma could relapse, mostly local, years after 
radical thymectomy. Adjuvant therapy did not prolong 
disease-free survival, whereas a re-resection could 
potentially improve long-term survival (from 73.6% 
to 82.4% at 5 years). About 40% of patients had an 
upgrade in the WHO class, which did not impact their 
prognosis (p. 1796).
In a study to determine the long-term (5 years and 10 years) 
outcomes in patients with recurrent thymoma after radical 
thymectomy, Sandri et al. conducted a retrospective analysis 
of 81 such patients on their clinicopathological characteristics 
and treatment received. Primary and recurrent thymomas were 
analyzed based on surgical and pathological criteria by Masaoka 
staging, and also subject to independent re-evaluation of histology 
by the World Health Organization (WHO) classification. The 
long-term survival and disease-free survival were assessed after 
initial thymectomy, and after treating for the relapse. The study 
population consisted of 54 patients with myasthenia gravis and 
•	 Clinical Characteristics 
and Outcomes for Patients 
with Thymic Carcinoma: 
evaluation of Masaoka 
staging
stage IVb lymph node (LN) involvement compared 
with those with distant metastasis (24% versus 7%, 
p = 0.025). Among patients with stage IVb disease, 
curative intent resection was conducted in 9% of those 
with distant metastasis (3 of 32), and 76% of those 
with LN-only disease (22 of 29). Of 22 patients with 
stage IVb LN-only disease who received multimodality 
therapy, 14% remain disease-free (3.4+ years to 6.8+ 
years). In conclusion, the findings demonstrated the 
prognostic value of Masaoka staging for OS and 
RFS in this patient population. Furthermore, the data 
suggested that patients with stage IVb LN disease could 
have better OS versus those with distant metastasis, 
and multimodality treatment could result in long-term 
disease-free survival in a subgroup of these patients. A 
revised staging system with stage IVb subdivided into 
two groups is suggested provided the results are further 
validated. This rare disease with high recurrence rates at 
all stages warrants future prospective trials to investigate 
treatments that will improve patient outcomes (p. 1810).
This study aimed to evaluate patient characteristics, recurrent-free 
survival (RFS), and overall survival (OS) in a large series of patients 
with thymic carcinomas in North America. The analysis of 121 
patients with the disease showed a significant association of higher 
Masaoka stage with worse OS and RFS at 5 years (both p < 0.001). 
Significantly improved 5-year OS was observed in patients with 
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rate of false-positive results (27.7% versus 22.0%; p 
< 0.001), higher lung cancer prevalence and positive 
predictive value (4.9% versus 3.0%), and lower 5-year 
all-cause survival (55.1% versus 64.1%; p = 0.018). Both 
cohorts showed similar resection rates for screen-detected 
cancer and low rates of complications from invasive 
procedures. Taken together, screening Medicare-eligible 
individuals detected more lung cancer than screening 
younger groups, despite the higher false-positive 
results. The authors suggest further understanding of 
risk and benefits of LDCT screening performance in 
Medicare-eligible groups by monitoring and assessing its 
performance outside the clinical trial setting.
Pinsky PF, Gierada DS, Hocking W, et al. National 
Lung Screening Trial Findings by Age: Medicare-
Eligible versus Under-65 Population. Ann Intern Med 
2014; doi:10.7326/M14-1484.
ReseARCh WATCh
•	 national Lung screening 
Trial Findings by Age: 
Medicare-eligible versus 
under-65 Population
This is a secondary analysis of the National Lung Screening Trial 
conducted by investigators from the Centers for Medicare and 
Medicaid Services to compare the screening performance using 
low-dose computed tomography (LDCT) in Medicare-eligible group 
(aged 65–74 years) versus those aged less than 65 years. Among 
participants randomly assigned to receive LDCT screening, 19,612 
were under 65 years old (under-65 cohort), whereas 7110 were more 
than 65 years old (over-65 cohort). Smoking and medical history, 
screening outcomes, lung cancer diagnosis and treatment, survival 
and mortality were compared between the two cohorts. Compared 
with the under-65 cohort, the over-65 cohort demonstrated a higher 
•	 erlotinib Alone or with 
Bevacizumab as First-Line 
Therapy in Patients with 
Advanced nonsquamous 
non–small-Cell Lung 
Cancer harboring eGFR 
Mutations (JO25567): An 
Open-Label, Randomized, 
Multicentre, Phase 2 study
a median progression-free survival of 16 months in the 
combination arm versus 9.7 months in the erlotinib 
alone arm (hazard ratio = 0.54; p = 0.0015). Rashes, 
hypertension, and proteinuria were the most common 
grade 3 or higher toxicities, whereas severe side effects 
were observed in both groups with similar frequency. 
The findings suggested that erlotinib plus bevacizumab 
could be a new first-line therapy that significantly 
improves progression-free survival of this patient 
population but warrant further studies to confirm.
Seto T, Kato T, Nishio M, et al. Erlotinib alone or 
with bevacizumab as first-line therapy in patients with 
advanced nonsquamous non–small-cell lung cancer 
harboring EGFR mutations (JO25567): an open-label, 
randomized, multicentre, phase 2 study. Lancet Oncol 
2014;15:1236–1244.
Seto et al. sought to compare the efficacy and safety of the 
combination of erlotinib and bevacizumab with erlotinib alone 
in the open-label, randomized, multicenter, phase 2 trial in 
patients with advanced nonsquamous non–small-cell lung 
cancer (NSCLC) bearing activating EGFR mutations, Eastern 
Cooperative Oncology Group performance status 0 or 1, and no 
prior chemotherapy in Japan. The analysis of 152 patients showed 
tobacco brand awareness (OR = 0.76, p < 0.01), to 
over-estimate peer smoking (OR = 0.84, p < 0.01), or be 
current smokers (OR = 0.73, p < 0.05), and for smokers 
to report thinking about smoking because of seeing PoS 
tobacco displays (OR = 0.60, p < 0.039). The impact of 
the ban was primarily apparent in most frequent visitors 
of tobacco retailers. The authors concluded that the bans 
on tobacco pack displays at retail environments could 
have a positive impact on youth’s tobacco pack exposure 
and potentially on smoking-related outcomes.
Dunlop S, Kite J, Grunseit AC, et al. Out of sight 
and out of mind? Evaluating the impact of point-of-sale 
tobacco display bans on smoking-related beliefs and 
behaviors in a sample of Australian adolescents and young 
adults. Nicotine Tob Res 2014; doi:10.1093/ntr/ntu180.
•	 Out of sight and Out 
of Mind? evaluating the 
Impact of Point-of-sale 
Tobacco Display Bans on 
smoking-Related Beliefs 
and Behaviors in a sample 
of Australian Adolescents 
and Young Adults
The authors sought to investigate the impact of the bans on tobacco 
pack displays at point-of-sale (PoS) on youth in New South Wales 
and Queensland, Australia. They analyzed the data from the annual 
cross-sectional survey of youth aged 12 to 24 years from 2010 
to 2012 (n = 6014). The results showed that the tendency was 
significantly lower after the ban versus before for youth to recall 
PoS tobacco displays (odds ratio, OR = 0.45, p < 0.01), to report 
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•	 American society for 
Radiation Oncology 
Annual Meeting 2014: use 
of Thoracic Radiotherapy 
for extensive stage small-
Cell Lung Cancer: A Phase 
3 Randomized Controlled 
Trial
and Belgium, who responded to chemotherapy and 
were treated with prophylactic cranial irradiation, to 
thoracic radiotherapy (30 Gy in 10 fractions) or without 
the treatment. Presented at the American Society for 
Radiation Oncology Annual Meeting and published 
simultaneously in The Lancet, the results of overall 
survival at 1 year did not significantly differ between 
groups (hazard ratio = 0.84; p = 0.066). However, 
thoracic radiotherapy did significantly improve the 2-year 
overall survival (13% versus 3%; p = 0.004), intrathoracic 
control (hazard ratio = 0.73; p = 0.001), and progression-
free survival at 6 months (24% versus 7%; p = 0.001). 
No severe adverse effects were reported. Based on the 
findings, the authors suggest that thoracic radiotherapy 
should be employed in addition to prophylactic cranial 
irradiation for all patients with extensive stage small-cell 
lung cancer with response to chemotherapy.
A phase 3 randomized controlled trial conducted by Slotman et al. 
showed mixed results when comparing thoracic radiotherapy with 
prophylactic cranial irradiation for the treatment of patients with 
extensive stage small-cell lung cancer. The trial randomized 495 
patients at 42 hospitals across the Netherlands, the UK, Norway, 
SPLC compared with current smokers (5-year incidence 
of SPLC: 7% and 0%, respectively, versus 13%). The 
study also found an increase of risk developing SPLC 
with the number of pack-years, i.e., 8% increase of 
risk per 10 pack-years. No association was observed 
between smoking history and local control and distant 
metastases. Overall survival was significantly poorer in 
current smokers compared with that in former smokers 
and never smokers. Taken together, the findings not 
only showed that compared with current smokers, 
never smokers had a low risk of not only developing 
SPLC after surgery and better overall survival but also 
indicated similar result for patients who quit smoking 
more than 5 years before surgery. This confirms the 
importance of smoking cessation in the care for patients 
and cancer survivors.
•	 American society for 
Radiation Oncology 
Annual Meeting 
2014: Tobacco use 
and secondary Lung 
Malignancies after surgery 
for non–small-Cell Lung 
Cancer
Boyle et al. set out to evaluate the association between smoking 
histories and the risk of developing secondary primary lung cancers 
(SPLC) in patients with stages I to IIIA non–small-cell lung 
cancer (consists of 372 current smokers, 1014 former smokers, 
and 98 never smokers) who had surgery, with or without adjuvant 
chemotherapy or radiotherapy. The analysis demonstrated that 
former smokers and never smokers were less likely to develop 
•	 esMO 2014: Programmed 
Cell-Death Ligand 1 
Protein: A Possible 
Immunotherapy Target in 
Mesothelioma
with patient outcome and survival. They reported that 
positive PD-L1 expression was found in 20.7% patients, 
of which 18.7% were strong, 25% were moderate, and 
56.2% were weak. PD-L1-positive patients had shorter 
median survival than the PD-L1-negative patients 
(4.79 versus 16.3 months). PD-L1 positivity was not 
associated with gender, smoking, asbestos exposure, and 
disease stage, but was more common in nonepithelial 
tumors than epithelial tumors. The findings could 
guide the selection of a subset of malignant pleural 
mesothelioma patients positive for PD-L1 with poorer 
outcomes to be treated with PD-L1-targeted therapies.
Cedres et al. analyzed programmed cell-death ligand 1 (PD-L1) 
expression in 119 patients with malignant pleural mesothelioma. 
Using anti-PD-L1 to detect PD-L1 expression, the intensity was 
scored as “0” for no expression, “1” for weak expression, “2” for 
moderate, and “3” for strong. The scores were then associated 
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•	 esMO 2014: A 
Randomized, Open-Label, 
Phase III Trial of Afatinib 
versus erlotinib as second-
Line Treatment of Patients 
with Advanced squamous 
Cell Carcinoma of the Lung 
After First-Line Platinum-
Based Chemotherapy: 
LuX-Lung 8
erlotinib. Stage IIIB/IV squamous cell carcinoma 
patients, who had no prior tyrosine kinase inhibitor 
therapy, were randomized to afatinib (n = 335) or 
erlotinib (n = 334) after disease progression following 
first-line platinum-based doublet chemotherapy. Median 
progression-free survival in the afatinib arm was 2.4 
months versus 1.9 months in the erlotinib arm (hazard 
ratio = 0.82; p = 0.043), and disease control rate was 
45.7% versus 36.8%, respectively; p = 0.020. Overall, 
safety profile was comparable between arms, with the 
afatinib arm experiencing more grade ≥3 diarrhea (9.7% 
versus 2.4%) and grade 3 stomatitis (3.3% versus 0%), 
and the erlotinib arm experiencing more grade 3 rash/
acne (5.5% versus 9.0%).
Goss et al. presented the results of LL8, which demonstrated that 
progression-free survival and disease control rate were significantly 
improved in patients with advanced squamous cell carcinoma 
receiving second-line afatinib versus those treated with second-line 
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•	 Investor-state Dispute 
settlement Provisions and 
Big Tobacco
Readers will recall previous reports on Investor-State Dispute 
Settlement (ISDS) provisions, contained within trade agreements 
that aim to protect companies from poor decisions made by the 
countries in which they invest. Previous reports (see June 2014 
Research Watch) have indicated potential abuse of these provisions 
by Big Tobacco with legal actions to prevent the adoption of 
tobacco control policies as part of major health initiatives. A 
report in the Washington Post discusses the ISDS provisions, 
illustrates the remarkable power they give to companies that 
use them (the suits are not heard in established courts but rather 
tribunals without recourse for appeal), and touches on the history 
of ISDS provisions in trade deals (a relatively recent development 
during the Reagan and first Bush administrations). As for Big 
Tobacco, a Philip Morris subsidiary challenged the 
Australian Government in court on packaging with 
health warnings and lost. A suit against the Australian 
Government under ISDS provisions is pending; New 
Zealand delayed the introduction of such graphic health 
warnings while awaiting the outcome of the Australian 
case. This is a compact and informative piece that helps 
with understanding the dense and complex world of 
trade agreements and why they are relevant to tobacco 
control. A major trade agreement (which was subject 
to the above-mentioned ISDS challenge from Philip 
Morris) is the Trans-Pacific Partnership. Currently, 
12 countries take part in the meetings including the 
United States, Australia, Brunei Darussalam, Canada, 
Chile, Japan, Malaysia, Mexico, New Zealand, Peru, 
Singapore, and Vietnam (http://www.ustr.gov/tpp). 
Readers who are acquiring a taste for international trade 
relations will be interested in following the upcoming 
Trans-Pacific Partnership Trade Ministers’ meeting to 
take place in Sydney from 25 October 2014.
http://www.washingtonpost.com/opinions/
harold-meyerson-allowing-foreign-firms-to-sue-
nations-hurts-trade-deals/2014/10/01/4b3725b0-4964-
11e4-891d-713f052086a0_story.html
